Pursuant to the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, the audio recording of the earnings conference call in respect of Unaudited Standalone and Consolidated Financial Results for the Quarter and nine months ended 31st December, 2024 held today i.e. 21st January, 2025 at 03:30 p.m. (IST) is available on the Company's website at https://www.indoco.com/inv-fin-concall-transcripts.asp. The Earnings Conference Call concluded at 04.20 p.m. (IST) on 21st January, 2025.

pdf

Indoco Remedies Ltd.

21 Jan 2025

229.66

-1.25%

Indoco Remedies Results Earnings Call for Q3FY25

Conference Call with Indoco Remedies Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.

Indoco Remedies Ltd.

21 Jan 2025

229.66

-1.25%

to see Rapid results content

Indoco Remedies Ltd.

21 Jan 2025

229.66

-1.25%

Corp. Note

INDOCO REMEDIES LTD. - 532612 - Integrated Filing (Financial)

BSE India

Integrated Financials for the quarter and nine months ended 31st December, 2024

pdf

Indoco Remedies Ltd.

21 Jan 2025

229.66

-1.25%

Result

INDOCO REMEDIES LTD. - 532612 - Unaudited Standalone And Consolidated Financial Results For The Quarter And …

BSE India

Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2024

pdf

Indoco Remedies Ltd.

21 Jan 2025

229.66

-1.25%

Board Meeting

INDOCO REMEDIES LTD. - 532612 - Board Meeting Outcome for Outcome Of Board Meeting Held On …

BSE India

Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 21st January, 2025 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2024 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results.

pdf

Indoco Remedies Ltd.

21 Jan 2025

229.66

-1.25%

Company Update

INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, this is to inform you that the Nomination and Remuneration Committee in its meeting held today i.e. 21st January, 2025 has approved the allotment of 65,700 equity shares of face value of Rs. 2 each to the Indoco Employees Welfare Trust under Indoco Remedies Limited Employee Stock Option Plan-2022.

pdf

Is Indoco Remedies Ltd. worth buying?

58 Votes:

Buy 74.14%

Sell 15.52%

Hold 10.34%

RESEARCH REPORTS

Not Rated SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf